KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Revenue (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Revenue data on record, last reported at $1.2 billion in Q4 2025.

  • For Q4 2025, Revenue rose 10.09% year-over-year to $1.2 billion; the TTM value through Dec 2025 reached $2.2 billion, down 44.86%, while the annual FY2025 figure was $4.3 billion, 4.88% up from the prior year.
  • Revenue reached $1.2 billion in Q4 2025 per JAZZ's latest filing, up from $1.0 billion in the prior quarter.
  • Across five years, Revenue topped out at $1.2 billion in Q4 2025 and bottomed at $607.6 million in Q1 2021.
  • Average Revenue over 5 years is $938.9 million, with a median of $949.0 million recorded in 2022.
  • Peak YoY movement for Revenue: skyrocketed 39.48% in 2021, then rose 1.03% in 2024.
  • A 5-year view of Revenue shows it stood at $896.7 million in 2021, then rose by 8.41% to $972.1 million in 2022, then rose by 4.1% to $1.0 billion in 2023, then grew by 7.53% to $1.1 billion in 2024, then increased by 10.09% to $1.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $1.2 billion in Q4 2025, $1.0 billion in Q2 2025, and $1.1 billion in Q4 2024.